Azarga approved by EMEA

Article

Azarga (brinzolamide 10mg/ml and timolol 5mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.

Azarga (brinzolamide 10 mg/ml and timolol 5 mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.

A clinical trial has demonstrated that Azarga is as safe as, but more effective than, either of its constituent components, brinzolamide and timolol. A separate study showed that Azarga is as safe as Cosopt (timolol/dorzolamide fixed combination; Merck), but is better tolerated and more comfortable for patients.

Azarga will be available in Europe from early next year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.